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ABSTRACT
Background: Patients with HBeAg-negative chronic hepatitis B (CHB) has a significantly 
different prognosis than inactive carriers; there is however, no reliable strategy for ac-
curately differentiating these two disease conditions.
Objectives: To determine a strategy for discriminating patients with HBeAg-negative 
CHB from inactive carriers.
Materials and Methods: Consecutive inactive carriers (i.e. HBeAg-negativity, anti-HBe-
positivity, normal ALT levels, and HBV DNA < 2000 IU/mL) were enrolled. HBV reactiva-
tion was defined as the elevation of the HBV DNA level to ≥ 2000 IU/mL. Patients were 
classified into true inactive carriers when their HBV DNA levels remained at < 2000 
IU/mL or false inactive carriers when their HBV DNA levels increased to ≥ 2000 IU/mL 
during the first year.
Results: The Mean ± SD age of 208 inactive carriers (140 males) was 47.7 ± 12.6 years. 
The Mean ± SD serum ALT and HBV DNA levels were 22.8 ± 8.6 IU/L and 360 ± 482 IU/
mL, respectively. HBV reactivation developed in 41 (19.7%) patients during the first year. 
Baseline HBV DNA and ALT levels differed significantly between true inactive and false 
inactive carriers. The AUROCs of the baseline ALT and HBV DNA levels for predicting a 
false inactive carrier were 0.609 and 0.831, respectively. HBV reactivation developed 
more often in patients with a baseline HBV DNA level of ≥ 200 IU/mL than in those 
with a baseline HBV DNA level of < 200 IU/mL during a Mean ± SD follow-up of 622 ± 
199 days.
Conclusions: The HBV DNA level was useful for discriminating patients with HBeAg-
negative CHB from true inactive carriers. The follow-up strategies applied to inactive 
carriers need to vary with their HBV DNA levels.
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Background
The loss of HBeAg in hepatitis B virus (HBV) carriers 
was  considered  a  sign  of  remission  of  hepatitis  and   Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co  All right reserved.Hepat Mon. 2011;11(5):351-357
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suppression  of  HBV  replication  (1,  2).  However,  the 
application  of  sensitive  methods  for  detecting  HBV 
in the serum showed that HBV could continuously or 
intermittently  replicate  even  in  an  HBeAg-negative 
patient  (3,  4).  HBeAg-negative  HBV  carriers  are  not 
a  homogeneous  group,  with  their  clinical  spectra 
ranging  from  inactive  carrier  to  aggressive  HBeAg-
negative hepatitis or cirrhosis (5, 6). The inactive carrier 
state  is  characterized  by  HBeAg-negativity  and  anti-
HBe-positivity,  low  or  undetectable  HBV  DNA,  normal 
alanine aminotransferase (ALT) levels, and inactive liver 
histology (7, 8). HBV carriers in this state usually have 
an excellent prognosis and rarely progress to cirrhosis 
or hepatocellular carcinoma (9, 10). Therefore, regular 
follow-up  is  recommended  without  antiviral  therapy 
(11, 12). In contrast, antiviral treatment is recommended 
for  patients  with  HBeAg-negative  chronic  hepatitis 
B  (CHB),  because  sustained  spontaneous  remission 
is  uncommon  and  their  long-term  prognosis  is  poor 
(13). Therefore, discrimination of patients with HBeAg-
negative  CHB  from  inactive  carriers  is  very  important 
for the improving of prognosis in HBV carriers. However, 
this might be difficult in some cases. The HBV DNA level is 
usually lower than in patients with HBeAg-positive CHB 
than in those with HBeAg-negative CHB (14). In addition, 
HBV  DNA  levels  can  fluctuate  widely  in  patients  with 
HBeAg-negative CHB (14, 15), which can result in some 
patients with HBeAg-negative CHB being misclassified as 
inactive carriers.
Because recent studies have suggested that the risks 
of  both  cirrhosis  and  hepatocellular  carcinoma  are 
significantly  higher  in  HBV  carriers  with  an  HBV  DNA 
level of ≥ 2000 IU/mL (7, 8, 16, 17), most of the recent 
guidelines  recommend  an  HBV  DNA  cutoff  level  for 
inactive carriers of 2000 IU/mL (11, 12). However, since 
HBV DNA levels can fluctuate to even lower than 2000 IU/
mL in patients with HBeAg-negative CHB, an HBV carrier 
should not be classified as being inactive solely based 
on a single HBV DNA reading of < 2000 IU/mL, which 
has  led  to  appropriate  follow-up  being  recommended 
for  differentiating  inactive  carriers  and  patients  with 
HBeAg-negative CHB (11, 12). However, the optimal follow-
up strategy for this differentiation remains uncertain. 
The American Association for the Study of Liver Diseases 
(AASLD) practice guideline recommends inactive carriers 
to be tested for ALT every three months during the first 
year to confirm that they are truly in the inactive carrier 
state, and then to repeat the test every 6−12 months (11). 
More recently, the European Association for the Study of 
the Liver (EASL) clinical practice guideline recommends 
a minimal follow-up of one year, with serum ALT and HBV 
DNA levels being measured every three months to detect 
fluctuations  of  activity  in  patients  with  active  HBeAg-
negative CHB (12).
Serum ALT levels may remain within the normal range 
for  long  periods  after  reactivation  of  HBV  replication 
(18). In addition, the serum ALT level was found to be 
normal in 20%−30% of patients with HBeAg-negative CHB 
at presentation (13). These features could result in some 
patients  with  HBeAg-negative  CHB  being  misclassified 
as inactive carriers when only serum ALT levels (i.e., not 
HBV DNA levels) are monitored. Although these patients 
could be appropriately classified with serial monitoring 
of  HBV  DNA  levels,  this  strategy  might  be  impossible 
in some cases because HBV DNA assays are not widely 
available and they are expensive. In addition, it is still 
uncertain whether this expensive test is necessary for 
differentiating these two disease conditions. This study 
was therefore performed to establish a follow-up strategy 
for  differentiating  patients  with  HBeAg-negative  CHB 
and true inactive carriers.
Patients and Methods
Patients
Between January 2006 and December 2007, consecutive 
untreated patients who were potential inactive carriers 
(defined as HBeAg-negativity, anti-HBe-positivity, normal 
ALT levels, and HBV DNA < 2000 IU/mL) were enrolled in 
this study. Exclusion criteria include previous diagnosis 
as  liver  cirrhosis  or  hepatocellular  carcinoma  and 
treatment  with  nucleoside  analogues,  interferon,  or 
immunosuppressive agents; alcohol abuse (daily alcohol 
intake > 60 g); and positivity for anti-hepatitis C virus 
antibody  or  anti-HIV.  Hepatitis  B  serologic  markers 
including HBsAg, HBeAg, and anti-HBe were tested using 
commercially available enzyme-linked immunosorbent 
assay kits (Abbott Laboratories, North Chicago, IL, USA). 
This study was conducted in full conformance with the 
ethical  guidelines  ofthe1975  Helsinki  Declaration  and 
was approved by our Institutional Review Board. Written 
informed consent was obtained from each participant.
Definition and classification
Patients  were  assessed  at  least  every  three  months 
if  there  were  any  clinical  indications  for  one  year  to 
determine if they were truly in the inactive carrier state. 
At each visit, serum ALT, bilirubin, albumin, and HBV DNA 
levels were checked. ALT, bilirubin, and albumin were 
measured by commercially available kits, with the upper 
limit of normal value (ULN) of ALT defined as 40 IU/L. HBV 
DNA quantification was performed by the COBAS TaqMan 
HBV DNA assay (Roche Diagnostics, Branchburg, NJ, USA; 
lower detection limit: 60 IU/mL). HBV reactivation was 
defined as elevation of the HBV DNA level to ≥ 2000 IU/
mL. Patients were classified according to their serum ALT 
or HBV DNA level during the first year into the normal 
ALT group, when their ALT levels remained within normal 
range during the first year, or the abnormal ALT group, 
when their ALT levels increased to > 40 IU/L during the 
first year, and into true inactive carriers when their HBV 
DNA levels remained at < 2000 IU/mL during the first 
year or false inactive carriers when their HBV DNA levels 
increased to ≥2000 IU/mL during the first year. Patients 
were followed until HBV DNA reactivation developed.Hepat Mon. 2011;11(5):351-357
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Statistical analysis
Continuous and categorical variables were expressed 
as Mean ± SD and number of patients (%), respectively. 
Differences  between  two  groups  were  analyzed  using 
the Mann-Whitney U or x2 test. Area under the receiver 
operating  characteristic  curve  (AUROC)  analysis  was 
performed  to  assess  the  predictive  efficacy  for  HBV 
reactivation. Cutoff values of HBV DNA for predicting HBV 
reactivation within one year were chosen for maximizing 
the  sum  of  sensitivity  and  specificity.  Kaplan-Meier 
method was used to assess the cumulative incidence of 
HBV reactivation. Univariate and multivariate analyses 
were performed to identify the factors associated with 
the development of HBV reactivation or abnormal ALT 
levels.  All  statistical  analyses  were  done  by  SPSS  ver 
13.0 (SPSS Inc., Chicago, IL, USA). A p value < 0.05 was 
considered statistically significant.
Results
Baseline characteristics
A  total  of  225  consecutive  inactive  carriers  were 
enrolled in this study. Their Mean±SD age was 48.2 ± 12.6 
years; 151 (67.1%) of studied patients were male. Seventeen 
(7.6%) patients were lost in follow-up in one year. HBV 
reactivation did not develop in these patients during a 
Mean ± SD follow-up of 138 ± 45 days. Although there was 
a trend for the Mean ± SD serum ALT level to be slightly 
lower in these patients than the remaining patients (18.6 
± 9.3 vs. 22.8 ± 8.7 IU/L, p = 0.058), the Mean ± SD serum HBV 
DNA level did not differ significantly between these two 
groups (449 ± 565 vs. 364 ± 483IU/mL; p = 0.314). These 17 
patients were excluded from further analyses. The Mean 
± SD age of the remaining 208 (140 male) patients who 
were followed for at least one year was 47.7 ± 12.6 years 
(Table 1). The Mean ± SD serum ALT and HBV DNA level was 
22.8 ± 8.6 IU/L and 360 ± 482 IU/mL, respectively. The HBV 
DNA level was ≥ 200 IU/mL in 86 (41.3%) patients.
In univariate linear regression analysis, sex and body 
mass index (BMI) were found to be significantly correlated 
with  serum  ALT  level,  but  not  with  age,  presence  of 
diabetes, and bilirubin, albumin, cholesterol, and HBV 
DNA levels. In multivariate linear regression analysis, BMI 
was the only independent factor significantly correlated 
with serum ALT level (β = 0.743; 95% confidence interval 
(CI): 0.347−1.138; p < 0.001) (Table 2).
Changes in serum ALT level within one year
Within one year, ALT level became abnormal in 18 (8.7%) 
patients  (abnormal  ALT  group)  but,  remained  within 
the ULN in 190 (91.3%) patients (normal ALT group). The 
prevalence of HBV reactivation within one year did not 
differ  significantly  (p  =  0.129)  between  the  abnormal 
ALT  group  (6  of  18  patients,  33%)  and  the  normal  ALT 
group (35 of 190 patients, 18%). At the time of abnormal 
ALT  measurements,  HBV  DNA  levels  were  >  2000  IU/L 
in only 6 of the 18 patients in the abnormal ALT group. 
BMI,  baseline  ALT  and  triglyceride  (TG)  levels  differed 
significantly  between  the  normal  and  abnormal  ALT 
groups, while age, sex, diabetes status, and the baseline 
cholesterol,  bilirubin,  albumin,  and  HBV  DNA  levels 
did not (Table1). In multivariate regression analysis, the 
baseline ALT (β = 0.121; OR = 1.128; 95% CI: 1.055−1.027; p < 
0.001) and TG (β = 0.015; OR = 1.015; 95% CI: 1.005−1.026; p = 
0.003) levels were found independent predictive factors 
for an abnormal ALT.
All patients 
(No. = 208)
Normal ALT a 
group (No. = 190)
Abnormal ALT a 
group (No. = 18)
p-value b True inactive 
carriers (No. = 167)
False inactive 
carriers (No. = 41)
p-value c
Age (years) 47.7 ± 12.6 48.1 ± 12.8 44.1 ± 9.7 0.114 48.0 ± 13.3 46.5 ± 9.6 0.242
Male [No. (%)] 140 (67.3) 127 (66.8) 13 (72.2) 0.642 114 (68.3) 26 (63.4) 0.553
Diabetes [No. (%)] 19 (9.2) 17 (9.0) 2 (11.1) 0.766 17 (10.2) 2 (5.0) 0.308
BMI (kg/m2) 23.6 ± 2.9 23.5 ± 2.9 24.9 ± 3.1 0.036 23.7 ± 3.1 23.4 ± 2.1 0.895
ALT (IU/L) 22.8 ± 8.6 22.0 ± 8.3 30.9 ± 7.8 < 0.001 22.2 ± 8.6 25.2 ± 8.3 0.031
Bilirubin (mg/dL) 0.8 ± 0.3 0.8 ± 0.3 0.8 ± 0.3 0.589 0.8 ± 0.3 0.8 ± 0.2 0.861
Albumin (g/dL) 4.6 ± 0.3 4.6 ± 0.3 4.6 ± 0.2 0.809 4.6 ± 0.3 4.6 ± 0.3 0.200
Cholesterol (mg/dL) 169.3 ± 30.4 168.5 ± 30.8 178.2 ± 25.0 0.184 169.0 ± 30.3 170.8 ± 31.2 0.982
Triglyceride (mg/
dL)
99.9 ± 44.9 95.9 ± 39.7 141.7 ± 70.4 0.001 100.6 ± 45.7 96.8 ± 42.0 0.521
Glucose (mg/dL) 98.4 ± 21.4 98.6 ± 22.1 96.3 ± 11.9 0.900 99.9 ± 23.0 92.1 ± 11.1 0.005
GGT (IU/L) 32.9 ± 37.0 30.0 ± 32.6 63.2 ± 61.5 0.002 31.9 ± 37.7 37.1 ± 34.1 0.090
HBV a DNA (IU/mL) 360 ± 482 348 ± 476 485 ± 546 0.633 248 ± 385 813 ± 570 < 0.001
Table 1. Baseline characteristics of HBV carriers according to the development of abnormal ALT levels or HBV reactivation within one year
a HBV: Hepatitis B virus; ALT: Alanine aminotransferase; BMI: Body mass index
b Difference between normal ALT group and abnormal ALT group
c Difference between true inactive carriers and false inactive carriers; normal ALT group: patients whose ALT level remained within normal range during the first year; 
abnormal ALT group: patients whose ALT level increased to > 40 IU/L during the first year; true inactive carriers: patients whose HBV DNA levels remained < 2000 IU/
mL during the first year; false inactive carriers: patients whose HBV increased to ≥ 2000 IU/mL during the first year.Hepat Mon. 2011;11(5):351-357
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Variable p-value a p-value b β (95% CI c)
Age 
(years)
0.342
Sex 0.007 0.083 2.206 ( 0.288 to 4.699)
BMI c 
(kg/m2)
< 0.001 < 0.001 0.743 (0.347 to 1.138)
Diabetes d 0.027 0.114
Bilirubin 
(mg/dL)
0.396
Albumin 
(g/dL)
0.735
Cholesterol 
(mg/dL)
0.415
Triglyceride 
(mg/dL)
0.024 0.323
HBV c DNA
(IU/mL)
0.404
Table 2. Univariate and multivariate linear regression analysis for baseline 
serum ALTa level
a p values for univariate linear regression analysis
b p values for multivariate linear regression analysis
c ALT: Alanine aminotransferase; BMI: Body mass index; CI: Confidence inter-
val; HBV: Hepatitis B virus
Cutoff value 
(IU/mL)
Sensitivity
 (%)
Specificity
 (%)
PPV a
 (%)
NPV a
 (%)
20 97.6 32.9 26.3 98.2
50 97.6 38.9 28.2 98.5
100 92.7 59.3 35.8 97.1
200 85.4 69.5 40.7 95.1
500 61.0 81.4 44.6 89.5
1,000 41.5 93.4 60.7 86.7
   
Table 3. Sensitivity, specificity, positive and negative predictive values for pre-
dicting HBVa reactivation within one year according to the different cutoff 
values of serum HBV DNA level
a HBV: HepatitisB virus, PPV: Positive predictive value, NPV: Negative predictive 
value
Development of HBV reactivation within one year
HBV  reactivation  developed  within  one  year  in  41 
(19.7%) patients (false inactive carriers): in 10, 14, 5, and 
12 patients at 3, 6, 9, and 12 months, respectively. HBeAg 
remained  negative  after  HBV  reactivation  in  these 
patients. The serum ALT level was abnormal at the time of 
HBV reactivation in 6 (15%) of 41 patients who were false 
inactive carriers. The Mean ± SD baseline HBV DNA level 
(248 ± 385 IU/mL vs. 813 ± 570 IU/mL, p < 0.001) and ALT 
(22.2 ± 8.6 IU/L vs. 25.2 ± 8.3 IU/L, p = 0.031) levels differed 
significantly  between  true  inactive  carriers  and  false 
inactive  carriers  (Table1).  The  area  under  the  receiver 
operator  characteristic  (AUROC)  of  the  baseline  HBV 
DNA  level  and  for  predicting  HBV  reactivation  during 
the  first  year  was  0.831  (95%  CI:  0.767−0.895)  (Figure. 
1).  With  a  cutoff  value  of  200  IU/mL,  the  sensitivity, 
specificity, positive predictive value (PPV), and negative 
predictive value (NPV) were 85.4%, 69.5%, 40.7%, and 95.1%, 
respectively (Table3). HBV reactivation developed in six 
(4.9%) patients with a baseline HBV DNA level of < 200 IU/
mL, and in 35 (41%) of patients with a baseline HBV DNA 
level of ≥ 200 IU/mL (p < 0.001) (Figure. 2).
The AUROC of the serum ALT level for predicting HBV 
reactivation  during  the  first  year  was  0.609  (95%  CI: 
0.512−0.706) (Figure. 1). With the optimal cutoff value of 
22.5  IU/L,  the  sensitivity,  specificity,  positive  predictive 
value, and negative predictive value were 68.3%, 59.9%, 
29.5%, and 88.5%, respectively.
Follow-up
The Mean ± SD total follow-up was 544 ± 243 days in all 
enrolled patients; it was 622 ± 199 days in true inactive 
carriers.  HBsAg  seroconversion  was  not  observed 
in  all  enrolled  patients  during  the  follow-up;  HBV 
reactivation  developed  in  55  patients.  The  cumulative 
incidences  of  HBV  reactivation  in  potential  inactive 
carriers were 8.7%, 16.3%, 24.4%, and 30.5% at 6, 12, 18, and 
24  months,  respectively.  The  cumulative  incidence  of 
HBV reactivation was significantly (p < 0.001) higher in 
patients with a baseline HBV DNA level of ≥ 200 IU/mL 
(33.7% and 62.6% at 12 and 24 months, respectively) than 
in those with a baseline HBV DNA level of < 200 IU/mL 
(4.1% and 8.7% at 12 and 24 months, respectively) (Figure 
3). Among 55 patients with HBV reactivation, serum ALT 
level increased in 17 patients during a Mean ± SD follow-
up of 525 ± 349 days after HBV reactivation. The Mean ± SD 
serum ALT and HBV DNA levels were 109 ± 69 IU/L and 5.7 
± 1.2 log10 IU/mL, respectively, at the time of ALT elevation. 
Ninety-five patients whose baseline HBV DNA level was < 
200 IU/mL in the inactive HBV group were followed for a 
Mean ± SD of 331 ± 186 more days after the first year. The 
HBV DNA level remained at < 200 IU/L during the first year 
in 75 patients and increased to ≥ 200 IU/mL in 20 patients. 
During the follow-up, HBV reactivation developed in 0%, 
11.5%, 17.8%, and 17.8% at 3, 6, 9, and 12 months after the first 
year in 20 patients whose HBV DNA levels increased to ≥ 
200 IU/mL during the first year; it did not develop in 75 
patients whose HBV DNA levels remained < 200 IU/mL 
during the first year (p = 0.002) (Figure 4).
Discussion
The  current  aim  of  managing  patients  with  chronic 
HBV infection is to prevent the disease progression into 
cirrhosis  and  HCC,  and  to  decrease  other  liver-related 
mortality by sustained suppression of HBV replication 
(11, 12). Several recent studies have indicated that the HBV 
DNA level is directly correlated with the risk of disease 
progression  in  HBV  carriers.  Recent  large  prospective 
cohort studies have suggested that the HBV DNA level 
is  a  prominent  risk  for  developing  HCC  (17)  and  liver 
cirrhosis  (16)  independently  of  the  HBeAg  status  and 
serum ALT level. Significant dose-response relationships 
between the serum HBV DNA level and the risk of HCC 
(17) and liver cirrhosis (16), have been found for HBV DNA Hepat Mon. 2011;11(5):351-357
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levels above 2000 IU/mL (16, 17). The cutoff value for the 
HBV DNA level of an inactive carrier has recently been 
recommended  to  be  2000  IU/mL.  This  management 
target could be considered in the long-term maintenance 
of patients with chronic HBV infection in the inactive 
carrier  state.  The  prognosis  of  inactive  carriers  is 
generally  favorable.  A  long-term  follow-up  study  of 
HBsAg-positive blood donors suggested that the survival 
rate did not differ between HBsAg-positive blood donors 
and  HBV-uninfected  controls  over  a  30-year  period 
(10).  In  addition,  most  patients  who  had  experienced 
spontaneous HBeAg seroconversion exhibited sustained 
remission during a median follow-up of nine years (9). 
However, some inactive carriers experience reactivation 
of  HBV  replication,  after  which  the  prognosis  usually 
worsens  (9,  19).  Therefore,  predicting  the  probability 
of HBV reactivation in HBV carriers with an HBV DNA 
level < 2000 IU/mL is very important when attempting 
to  design  an  appropriate  follow-up  schedule  and  to 
estimate prognosis.
The AASLD guideline recommends that inactive carriers 
should be monitored (including ALT levels) every three 
months during the first year to confirm that they are 
truly in the “inactive carrier state” and every 6−12 months 
thereafter. It is recommended that HBV DNA levels be 
monitored if the elevation of serum ALT level persists 
or  recurs  (11).  In  the  present  study,  HBV  reactivation 
developed in 19.7% of those in the normal ALT group, who 
could be considered to be truly in the “inactive carrier 
state” according to the AASLD guideline, while the HBV 
DNA level remained < 2000 IU/mL during the first year 
in 33.3% of those in the abnormal ALT group. In addition, 
the  serum  ALT  level  was  not  useful  for  detecting  or 
predicting HBV reactivation in our study. The AUROC for 
HBV reactivation within one year was only 0.609. HBV 
DNA  levels  remained  stable  in  66.7%  of  patients  with 
abnormal ALT levels, and HBV reactivation developed in 
18.4% of patients with an ALT level that remained normal 
for  one  year.  Using  the  recently  recommended  ULNs 
of ALT (30 IU/L for men and 19 IU/L for women) did not 
improve the sensitivity, specificity, PPV, and NPV, which 
were 41.5%, 83.6%, 27.4%, and 83.6%, respectively (data not 
shown). Our results are consistent with a recent study 
finding that one-third of patients with HBeAg-negative 
CHB experienced serum HBV DNA levels < 2000 IU/mL at 
least once during their follow-up, and that 22% of these 
cases  presented  with  persistently  abnormal  ALT  levels 
(8).  Other  studies  have  also  suggested  that  a  normal 
ALT level alone is not an accurate indicator of inactive 
disease (20, 21). Therefore, only serial measurements of 
serum ALT level might not be enough for differentiating 
HBV  carriers  who  are  “truly”  in  the  inactive  HBV 
replication state from HBeAg-negative CHB patients. On 
the other hand, the EASL guideline suggests that careful 
assessment of inactive carriers is needed, with a minimal 
follow-up of one year and serum ALT and HBV DNA levels 
being  measured  every  three  months  usually  allowing 
fluctuations  of  activity  in  patients  with  active  HBeAg-
negative CHB to be detected (12). However, this strategy 
with  frequent  monitoring  using  expensive  HBV  DNA 
tests might not be cost-effective, and in some cases might 
even be impossible for the high cost. Therefore, a more 
efficient follow-up strategy is needed.
In the present study, baseline HBV DNA and ALT levels 
differed  significantly  between  true  inactive  and  false 
inactive carriers. However, the predictive efficacy of the 
baseline ALT level for false inactive carriers was low, with 
an AUROC of only 0.609. In contrast, the baseline HBV 
DNA level was found to be very useful for discriminating 
false inactive carriers from true inactive carriers—most 
of inactive carriers could be discriminated using a cutoff 
Figure 1. Area under receiver operating characteristic curve for hepatitis 
B virus (HBV) reactivation of baseline HBV DNA and ALT levels. ALT: Alanine 
aminotransferase
Figure2. Incidence of hepatitis B virus (HBV) reactivation within one year ac-
cording to the baseline HBV DNA level
P < 0.001
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value  of  200  IU/mL.  In  addition,  HBV  reactivation  did 
not develop during the following year in HBV carriers 
whose HBV DNA level remained < 200 IU/mL within the 
first year. However, the risk of HBV reactivation increased 
when the HBV DNA level was ≥ 200 IU/mL at any time 
during follow-up. Therefore, the follow-up strategy for 
detecting inactive carriers might need to differ based on 
the HBV DNA levels: in HBV carriers with an HBV DNA level 
< 200 IU/mL, yearly follow-up of HBV DNA levels seems to 
be sufficient for detecting HBV reactivation; if HBV DNA 
level is ≥ 200 IU/mL, 6-monthly follow-up of HBV DNA 
levels might be more appropriate.
A recent study suggested that the serum HBV DNA level 
was higher in those with high-normal ALT (≥ 0.5×ULN) 
than  in  those  with  low-normal  ALT  (<  0.5×ULN)  (5), 
which  is  inconsistent  with  the  results  of  our  study 
(where the serum ALT level was not correlated with the 
HBV DNA level). This discrepancy might be due to the use 
of different definitions for inactive carriers. The range 
of  HBV  DNA  levels  was  narrower  in  the  present  study 
because  we  defined  the  ULN  of  the  HBV  DNA  level  in 
an inactive carrier as < 2000 IU/mL, while the previous 
study  enrolled  patients  with  HBeAg-negativity  and 
persistently  normal  ALT  level  regardless  of  their  HBV 
DNA level (5). This discrepancy in the study design might 
have lessened the effect of HBV DNA level on serum ALT 
level in our patients. However, consistent finding of the 
previous study was that a serum HBV DNA level ≥ 2000 
IU/mL was independently associated with high-normal 
ALT  levels  (5).  Our  study  excluded  patients  with  HBV 
DNA level ≥ 2000 IU/mL. Another possible explanation 
for  the  observed  discrepancy  is  that  in  our  study  the 
baseline  ALT  and  TG  levels  were  significant  predictive 
factors for an abnormal ALT groups and only BMI being 
significantly  associated  with  the  baseline  ALT  level. 
Elevated TG level and BMI are associated with hepatic 
steatosis in CHB patients (22-24). Because BMI was not 
reported for the previous studies, direct comparison was 
not possible. However, according to our results, the effect 
of HBV DNA level was minimal and serum ALT levels were 
influenced mainly by fatty liver disease in HBV carriers 
with an HBV DNA level < 2000 IU/mL. That is, serum ALT 
level is influenced by not only the HBV DNA level but 
also the degree of fatty liver disease, and this might have 
also led to the low predictive value of serum ALT levels 
for HBV reactivation in our results. The main limitation 
of our study was the short duration of follow-up in our 
patients: all enrolled patients and true inactive carriers 
were followed for a Mean ± SD of 544 ± 243 and 622 ± 199 
days, respectively. Further studies with longer follow-up 
duration are needed to confirm our results. 
In conclusion, we found that HBV DNA level is a useful 
mean for discriminating patients with HBeAg-negative 
CHB from true inactive carriers. The follow-up strategy 
applied  to  inactive  carriers  need  to  vary  according  to 
their HBV DNA levels.
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